Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Baird Maintains Outperform on CarMax, Lowers Price Target to $82

Baird Maintains Outperform on CarMax, Lowers Price Target to $82

Baird analyst Craig Kennison maintains CarMax (NYSE:KMX) with a Outperform and lowers the price target from $120 to $82.

byBenzinga Newsdesk

September 30, 2022

1 minute read

Baird analyst Craig Kennison maintains CarMax (NYSE:KMX) with a Outperform and lowers the price target from $120 to $82.

FDA
News

Astrazeneca Announced Truqap Approved In US For HR+ Breast Cancer

By Charles Gross

November 17, 6:12 AM

AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or

AZN

Analyst Ratings

What 19 Analyst Ratings Have To Say About Fidelity National Info

By Benzinga Insights

November 4, 3:13 PM

Analysts have provided the following ratings for Fidelity National Info (NYSE:FIS) within the last quarter:

FIS

Raymond James Upgrades Silvercorp Metals to Outperform, Raises Price Target to C$6.15

By Benzinga Newsdesk

January 31, 9:14 AM

Raymond James upgrades Silvercorp Metals (TSX:SVM) from Market Perform to Outperform and raises the price target from C$5 to C$6.15.

TSX:SVM

Analyst Ratings

Where SolarEdge Technologies Stands With Analysts

By Benzinga Insights

August 3, 10:53 AM

Analysts have provided the following ratings for SolarEdge Technologies (NASDAQ:SEDG) within the last quarter:

SEDG

Baird Maintains Outperform on CarMax, Lowers Price Target to $82

Related Posts

Astrazeneca Announced Truqap Approved In US For HR+ Breast Cancer

What 19 Analyst Ratings Have To Say About Fidelity National Info

Raymond James Upgrades Silvercorp Metals to Outperform, Raises Price Target to C$6.15

Where SolarEdge Technologies Stands With Analysts